李斌，谢俊刚，陈奇，志尹莹，，罗光伟，贾珉，梁亚光.穴位疗法对支气管哮喘缓解期患者炎症因子及临床疗效的影响[J].中华物理医学与康复杂志,2016,38(12):920-923
扫码阅读全文
|
| 穴位疗法对支气管哮喘缓解期患者炎症因子及临床疗效的影响 |
|
| |
| DOI： |
| 中文关键词: 穴位疗法 哮喘 白细胞介素 |
| 英文关键词: Acupoint therapy Asthma Interleukin-5 Interleukin-10 |
| 基金项目:武汉市卫计委资助项目（WZ14B06） |
|
| 摘要点击次数: 2202 |
| 全文下载次数: 3096 |
| 中文摘要: |
| 目的探讨穴位疗法对支气管哮喘缓解期患者炎症因子及临床疗效的影响。 方法将入选的支气管哮喘缓解期患者按随机数字表法分为治疗组和对照组，每组30例，治疗组给予穴位疗法，对照组给予舒利迭治疗，共治疗4周。观测2组患者治疗前、治疗1个月后（近期）和停止治疗3个月后（远期）的哮喘控制测试（ACT）积分、治疗1个月后（近期）哮喘控制情况（完全控制、部分控制、未控制）以及患者治疗前、治疗1个月后（近期）和停止治疗3个月后（远期）的白介素5（IL-5）、白介素10（IL-10）的含量，并对2组患者的ACT积分、近期疗效及IL-5和IL-10的含量进行统计学分析比较。 结果①治疗前，治疗组和对照组患者的ACT积分分别为（14.11±3.24）和（13.75±3.02）分，组间差异无统计学意义（P>0.05）。治疗后，治疗组近期和远期的ACT积分［（21.56±1.81）和（24.03±0.78）分］均明显高于同期对照组［（18.71±1.63）和（22.15±0.96）分］，组间差异有统计学意义（P<0.05)；②治疗组近期控制哮喘的总有效率（93.33%）明显高于对照组（70.00%），且组间差异有统计学意义（χ2＝5.455，P<0.05）；③治疗组治疗后近期和远期的IL-5和IL-10炎症因子的含量较组内治疗前明显改善且优于同期对照组（P<0.05）。 结论穴位疗法通过调节IL-5和IL-10炎症因子含量水平，降低气道炎症，控制支气管哮喘症状，提高患者的临床疗效。 |
| 英文摘要: |
| Objective To investigate the effects of acupoint therapy on inflammatory factors and its clinical efficacy in relieving bronchial asthma. MethodsSelected patients with bronchial asthma which was in remission were randomly divided into a treatment group that was treated with acupoint therapy and a control group that was given Seretide. Each group had 30 cases. The treatment period was 4 weeks. Both groups were evaluated in terms of Asthma Control Test (ACT) scores and the serum content of interleukin-5 (IL-5) and interleukin-10 (IL-10) before and at one month (short-term), as well as three months after the end of the treatment (long-term). The asthma control situation (fully controlled, partially controlled or uncontrolled) was evaluated. Results Before treatment the average ACT scores of the two groups were not significantly different. After the treatment both the short-term and long-term average ACT scores of the treatment group were significantly higher than those of the control group. The total effectiveness rate of asthma control in the treatment group in the short term (93%) was significantly higher than that in the control group (70%). After the treatment the IL-5 and IL-10 levels in the treatment group were improved to a significantly greater extent than those in the control group. Conclusion Acupoint therapy can reduce airway inflammation, control bronchial asthma symptoms and show good clinical efficacy, probably by regulating IL-5 and IL-10 levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
